GlassScriptPhysician profile
Robert J Summerlee
NPI 1174596050
$1,381.35
in general payments reported to CMS, 2019-2025
19 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $127 · 2022: $151 · 2023: $131 · 2024: $375 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.74 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Pfizer INC. | $189.66 | 2019-2024 | |
| Boston Scientific Corporation | $173.73 | 2019-2024 | Autocap Rx, Interject |
| Aimmune Therapeutics, INC. | $143.22 | 2024 | |
| Janssen Biotech, INC. | $116.64 | 2020-2025 | Tremfya |
| Gilead Sciences, INC. | $64.57 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.28 | 2019-2025 | Eohilia, Entyvio |
| Braintree Laboratories, INC. | $31.23 | 2019-2025 | Suflave, Sutab |
| Mauna Kea Technologies, INC. | $27.85 | 2024 | |
| Intercept Pharmaceuticals, INC. | $21.26 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.25 | 2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.31 | 2025 | Spevigo |
| Beta Bionics, INC. | $18.76 | 2023 | Ilet Bionic Pancreas |
| Ipsen Biopharmaceuticals, INC | $17.60 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $17.06 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.46 | 2023 | Xifaxan |
| Exact Sciences Corporation | $14.60 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $12.78 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Summerlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.